PTK2B and prostate carcinoma: Through activating Pyk2, elevated ErbB‐2 could increase the ERK/MAPK activity and enhance cell adhesive ability and metastasis in human prostate cancer (PCa), while FAK isn't correlated with PCa cell adhesive ability (Yuan et al., 2007).